Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Validating Stat3 in cancer therapy

Nature Medicine volume 11, pages 595–596 (2005)Cite this article

The transcription factor STAT3 is overactive in many tumors and has attracted attention as a drug target. But in vivo evidence suggesting that inhibiting STAT3 could counteract cancer has been incomplete. The picture in the whole animal now begins to clarify, and it bodes well for this approach (pages 623–629).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Normal activation-inactivation cycle of STAT3 and potential errors in regulation in cancer.

Katie Ris

References

  1. Yu, H. & Jove, R. Nat. Rev. Cancer 4, 97–105 (2004).

    Article  CAS  Google Scholar 

  2. Levy, D. & Darnell, J.E., Jr. Nat. Rev. Mol. Cell Biol. 3, 651–662 (2002).

    Article  CAS  Google Scholar 

  3. Darnell, J.E., Jr. Nat. Rev. Cancer 2, 740–749 (2002).

    Article  CAS  Google Scholar 

  4. Chan, K.S. J. Clin. Invest. 114, 720–728 (2004).

    Article  CAS  Google Scholar 

  5. Chiarle, R. et al. Nat. Med. 11, 623–629 (2005).

    Article  CAS  Google Scholar 

  6. Bromberg, J.F. et al. Cell 98, 295–303 (1999).

    Article  CAS  Google Scholar 

  7. Yoshikawa, H. et al. Nat. Genet. 28, 29–35 (2001).

    CAS  Google Scholar 

  8. He, B. et al. Proc. Natl. Acad. Sci. USA 100, 14133–14138 (2003).

    Article  CAS  Google Scholar 

  9. Zhang, Q. et al. J. Immunol. 168, 466–474 (2002).

    Article  CAS  Google Scholar 

  10. Morris, S.W. Science 263, 1281–1284 (1994).

    Article  CAS  Google Scholar 

  11. Xi, S., Gooding, W.E. & Grandis, J.R. Oncogene 24, 970–979 (2005).

    Article  CAS  Google Scholar 

  12. Turkson, J. et al. Mol. Cancer Ther. 3, 1533–1542 (2004).

    CAS  PubMed  Google Scholar 

  13. Sun, J. et al. Oncogene 24, 1–10 (2005).

    CAS  Google Scholar 

  14. Song, H., Wang, R., Wang, S. & Lin, J. Proc. Natl. Acad. Sci. USA 102, 4700–4705 (2005).

    Article  CAS  Google Scholar 

  15. Zhong, M. et al. Proc. Natl. Acad. Sci. USA 102, 3966–3971 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rockefeller University, New York, 10021, New York, USA

    James E Darnell Jr

Authors
  1. James E Darnell Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Darnell, J. Validating Stat3 in cancer therapy. Nat Med 11, 595–596 (2005). https://doi.org/10.1038/nm0605-595

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0605-595

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing